HK1011291A1 - Improvements in or relating to organic compositions - Google Patents

Improvements in or relating to organic compositions

Info

Publication number
HK1011291A1
HK1011291A1 HK98112458A HK98112458A HK1011291A1 HK 1011291 A1 HK1011291 A1 HK 1011291A1 HK 98112458 A HK98112458 A HK 98112458A HK 98112458 A HK98112458 A HK 98112458A HK 1011291 A1 HK1011291 A1 HK 1011291A1
Authority
HK
Hong Kong
Prior art keywords
relating
organic compositions
granules
andb
comprisinga
Prior art date
Application number
HK98112458A
Other languages
English (en)
Inventor
Peter William Dettmar
Paul Andrew Dickson
Frank Chadwick Hampson
Ian Gordon Jolliffe
William Peers
Original Assignee
Reckitt & Colmann Prod Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reckitt & Colmann Prod Ltd filed Critical Reckitt & Colmann Prod Ltd
Publication of HK1011291A1 publication Critical patent/HK1011291A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Dental Preparations (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK98112458A 1995-03-13 1998-11-30 Improvements in or relating to organic compositions HK1011291A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9505032.4A GB9505032D0 (en) 1995-03-13 1995-03-13 Improvements in or relating to organic compositions

Publications (1)

Publication Number Publication Date
HK1011291A1 true HK1011291A1 (en) 1999-07-09

Family

ID=10771122

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98112458A HK1011291A1 (en) 1995-03-13 1998-11-30 Improvements in or relating to organic compositions

Country Status (21)

Country Link
US (1) US6306789B1 (de)
EP (1) EP0814771B1 (de)
JP (1) JPH11501652A (de)
KR (1) KR19980702970A (de)
CN (1) CN1126533C (de)
AT (1) ATE212539T1 (de)
AU (1) AU712464B2 (de)
BR (1) BR9607234A (de)
CZ (1) CZ274497A3 (de)
DE (1) DE69618934T2 (de)
ES (1) ES2167546T3 (de)
GB (2) GB9505032D0 (de)
HK (1) HK1011291A1 (de)
HU (1) HUP9900800A3 (de)
MX (1) MX9706992A (de)
NO (1) NO974194L (de)
NZ (1) NZ302741A (de)
PL (1) PL184407B1 (de)
TR (1) TR199700943T1 (de)
WO (1) WO1996028141A1 (de)
ZA (1) ZA962012B (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1203846C (zh) * 1998-03-19 2005-06-01 布里斯托尔-迈尔斯斯奎布公司 高溶解性药物的双相控释递送系统和方法
GB9809347D0 (en) * 1998-05-05 1998-07-01 Reckitt & Colmann Prod Ltd Compositions
IN190017B (de) * 1999-01-25 2003-05-31 Panacea Biotech Ltd
JP2004513975A (ja) 2000-12-05 2004-05-13 マクグレゴール アレキサンダー 作用物質の制御放出のための静水圧デリバリシステム
AU2002319653A1 (en) * 2001-07-20 2003-03-03 Samir Mitragotri Method for oral drug delivery
US6572889B1 (en) * 2002-03-07 2003-06-03 Noveon Ip Holdings Corp. Controlled release solid dosage carbamazepine formulations
US7198653B2 (en) 2003-07-31 2007-04-03 Delavau Llc Calcium carbonate granulation
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US9138414B1 (en) 2006-09-15 2015-09-22 Delavau Llc Calcium supplement having enhanced absorption
EP2942053A1 (de) 2007-07-06 2015-11-11 Lupin Limited Pharmazeutische Zusammensetzungen zur Wirkstoffverabreichung im Magen-Darm-Trakt
US20120027855A1 (en) 2007-07-06 2012-02-02 Lupin Limited Pharmaceutical compositions for gastrointestinal drug delivery
US8974825B2 (en) * 2007-07-06 2015-03-10 Lupin Limited Pharmaceutical compositions for gastrointestinal drug delivery
US20090123390A1 (en) * 2007-11-13 2009-05-14 Meritage Pharma, Inc. Compositions for the treatment of gastrointestinal inflammation
ES2729925T3 (es) 2007-11-13 2019-11-07 Meritage Pharma Inc Composiciones de corticosteroides
US20100216754A1 (en) * 2007-11-13 2010-08-26 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
US20090123551A1 (en) * 2007-11-13 2009-05-14 Meritage Pharma, Inc. Gastrointestinal delivery systems
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
US20090264392A1 (en) * 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis
CA2721927C (en) 2008-04-21 2014-01-28 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
US8784870B2 (en) * 2008-07-21 2014-07-22 Otonomy, Inc. Controlled release compositions for modulating free-radical induced damage and methods of use thereof
US10092580B2 (en) 2008-07-21 2018-10-09 Otonomy, Inc. Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders
LT2328553T (lt) 2008-08-20 2020-09-10 The Regents Of The University Of California Kortikosteroidai, skirti virškinimo trakto uždegiminių ligų gydymui
JP6552115B2 (ja) * 2013-03-15 2019-07-31 クック・メディカル・テクノロジーズ・リミテッド・ライアビリティ・カンパニーCook Medical Technologies Llc 消化管病変を治療するための接着性医療製品及び方法
US11931227B2 (en) 2013-03-15 2024-03-19 Cook Medical Technologies Llc Bimodal treatment methods and compositions for gastrointestinal lesions with active bleeding
CA2993645A1 (en) 2015-07-28 2017-02-02 Otonomy, Inc. Trkb or trkc agonist compositions and methods for the treatment of otic conditions
CA3029281A1 (en) 2016-06-29 2018-01-04 Otonomy, Inc. Triglyceride otic formulations and uses thereof
US11452798B2 (en) 2017-09-27 2022-09-27 Cook Medical Technologies Llc Crosslinking submucosal injectate system
JP7497289B2 (ja) 2018-01-09 2024-06-10 ドンペ ファーマシューティシ エス.ピー.エー. 成長因子耳用製剤
WO2019154895A1 (en) 2018-02-08 2019-08-15 Strekin Ag Gel formulation for preventing or treating hearing loss
CN114904007B (zh) * 2022-04-24 2024-04-05 南京紫鸿生物科技有限公司 一种提高卡波姆的堆积密度的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60237054A (ja) 1984-05-10 1985-11-25 Nippon Kayaku Co Ltd アミノ酸の晶析法
GB8428952D0 (en) 1984-11-16 1984-12-27 Beecham Group Plc Formulations
US4772475A (en) * 1985-03-08 1988-09-20 Yamanouchi Pharmaceutical Co., Ltd. Controlled-release multiple units pharmaceutical formulation
US5057317A (en) 1987-03-24 1991-10-15 Chugai Seiyaku Kabushiki Kaisha Slow-release pharmaceutical agent
EP0297866A3 (de) 1987-07-01 1989-12-13 The Boots Company PLC Arzneimittel
GB9010039D0 (en) * 1990-05-03 1990-06-27 Reckitt & Colmann Prod Ltd Medicament preparation
DE4036757A1 (de) * 1990-11-17 1992-05-21 Bayer Ag Antazida-zubereitung mit verlaengerter magenverweilzeit
TW209174B (de) * 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
US5350584A (en) * 1992-06-26 1994-09-27 Merck & Co., Inc. Spheronization process using charged resins
DE69424487T2 (de) * 1993-09-09 2001-01-18 Takeda Chemical Industries, Ltd. Formulierung enthaltend einen antibakteriellen und einen Antiulcus Wirkstoff

Also Published As

Publication number Publication date
NZ302741A (en) 1999-08-30
ATE212539T1 (de) 2002-02-15
DE69618934T2 (de) 2002-09-12
AU4886896A (en) 1996-10-02
HUP9900800A3 (en) 2001-02-28
JPH11501652A (ja) 1999-02-09
DE69618934D1 (de) 2002-03-14
WO1996028141A1 (en) 1996-09-19
NO974194D0 (no) 1997-09-11
HUP9900800A2 (hu) 1999-07-28
ES2167546T3 (es) 2002-05-16
GB9505032D0 (en) 1995-05-03
US6306789B1 (en) 2001-10-23
PL184407B1 (pl) 2002-10-31
CN1126533C (zh) 2003-11-05
PL322065A1 (en) 1998-01-05
KR19980702970A (ko) 1998-09-05
MX9706992A (es) 1997-11-29
CZ274497A3 (cs) 1998-03-18
AU712464B2 (en) 1999-11-04
GB9604678D0 (en) 1996-05-01
NO974194L (no) 1997-09-11
GB2298790B (en) 1999-06-30
ZA962012B (en) 1996-09-26
EP0814771B1 (de) 2002-01-30
GB2298790A (en) 1996-09-18
EP0814771A1 (de) 1998-01-07
CN1178458A (zh) 1998-04-08
TR199700943T1 (xx) 1998-02-21
BR9607234A (pt) 1997-11-11

Similar Documents

Publication Publication Date Title
GB2298790B (en) Improvements in or relating to organic compositions
AU4063697A (en) Methods for regulating gastrointestinal motility
CA2342340A1 (en) New sustained release oral formulations
IL135258A0 (en) Bioadhesive compositions and methods for topical administration of active agents
CA2361716A1 (en) Method of preparing alkylated salicylamides
DK1183014T3 (da) Smagsmaskerede orale farmaceutiske sammensætninger med kontrolleret frigivelse
WO1997038662A3 (en) Buccal polar spray or capsule
CA2131350A1 (en) Sustained release drug formulation containing a tramadol salt
TW355683B (en) Composition containing micronized nebivolol
GB0122318D0 (en) Organic compounds
BR0311530A (pt) Compostos e método de liberação para droga transmucosal e para crio-proteção
IL150895A0 (en) Oral, nasal and pulmonary formulations of copolymer-1
CA2326198A1 (en) Cosolvent formulations
IL101056A (en) Composition for nasal treatment
WO2000013662A8 (en) Medicated chewing gum delivery system for nicotine
PL1608349T3 (pl) Układ do ustnego dostarczania zawierający środek przeciwbakteryjny i środek przeciwzapalny
IL142284A0 (en) A pharmaceutical composition containing an agent which blocks the binding of lymphotoxin-b to its receptor
AP1485A (en) Orally administered controlled delivery system for once daily administration of ciprofloxacin.
CA2214979A1 (en) Improvements in or relating to organic compositions
WO2003040316A3 (en) Selective elimination of cd52+ cells and uses thereof
CA2252038A1 (en) Buccal polar spray or capsule
EP1393724A3 (de) Neue Formulierungen zur transdermale Verabreichung von Fluoxetin

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20040305

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)